Home › Treatment Comparison › Jublia vs Terbinafine

Jublia vs Terbinafine (2026): Evidence-Graded Prescription Comparison

Plain topical solution bottle beside a pill bottle, comparing a topical and an oral nail antifungal

The Short Answer

Terbinafine (oral) Strong Evidence — ~38% complete cure in the FDA label trials (Lamisil prescribing information) — is first-line for most healthy adults with toenail fungus. Jublia (efinaconazole 10% topical) Moderate Evidence — 15–18% complete cure (Elewski, JAAD 2013) — is a prescription topical that avoids systemic drug exposure. Oral terbinafine has better efficacy; Jublia is preferred when systemic treatment is not suitable (liver concerns, drug interactions, patient preference for topical).

Both require a prescription. Neither is available OTC.

At a Glance

Side by Side

  • Jublia (topical): Moderate evidence; 15–18% complete cure; 48 weeks daily; minimal systemic exposure
  • Terbinafine (oral): Strong evidence; ~38% complete cure (FDA label); 12 weeks; liver tests required

Key Facts

Most healthy adults

Terbinafine (first-line)

Liver concerns or interactions

Jublia

Lower cost

Terbinafine generic ~$10–$40

Prescription

Both; neither is OTC

Jublia vs Terbinafine at a Glance

Side by side:

  • Type: Jublia (efinaconazole 10%): Prescription topical solution; Terbinafine (oral): Prescription oral tablet
  • Drug class: Jublia (efinaconazole 10%): Triazole antifungal; Terbinafine (oral): Allylamine antifungal
  • Mechanism: Jublia (efinaconazole 10%): Inhibits ergosterol synthesis (CYP51); Terbinafine (oral): Inhibits squalene epoxidase; fungicidal
  • Evidence grade: Jublia (efinaconazole 10%): Moderate evidence; Terbinafine (oral): Strong evidence
  • Complete cure rate: Jublia (efinaconazole 10%): 15–18%; Terbinafine (oral): ~38% at 48 wks (FDA label)
  • Treatment duration: Jublia (efinaconazole 10%): 48 weeks (daily application); Terbinafine (oral): 12 weeks (toenail)
  • Systemic exposure: Jublia (efinaconazole 10%): Minimal; Terbinafine (oral): Significant (hepatic metabolism)
  • Liver monitoring: Jublia (efinaconazole 10%): Not routinely required; Terbinafine (oral): Required; rare hepatotoxicity risk
  • Drug interactions: Jublia (efinaconazole 10%): Minimal systemic interactions; Terbinafine (oral): CYP2D6 interactions; warfarin interaction possible
  • Typical cost: Jublia (efinaconazole 10%): High brand cost; check GoodRx; Terbinafine (oral): Generic available; ~$10–$40/course (GoodRx)
  • Rx required: Jublia (efinaconazole 10%): Yes; Terbinafine (oral): Yes

Jublia vs Terbinafine: Head-to-Head

Jublia (Efinaconazole 10%)

VS

Terbinafine (Oral)

Verdict: For efficacy: oral terbinafine (~38% vs 15–18%). For safety profile in liver-sensitive or multi-drug patients: Jublia. Both require a prescription. See your healthcare provider for the right choice for you. Full treatment comparison →

How Jublia (Efinaconazole 10%) Works

Moderate Evidence — Jublia (efinaconazole 10% solution) is an FDA-approved prescription topical antifungal for toenail onychomycosis. It is a triazole antifungal that inhibits ergosterol synthesis via CYP51A1 (lanosterol 14-alpha-demethylase), disrupting the fungal cell membrane.

Diagram of a topical reaching fungus through the nail versus a pill reaching it through the blood

How Oral Terbinafine Works

Strong Evidence — Oral terbinafine is an allylamine antifungal. It inhibits squalene epoxidase, an enzyme critical to fungal cell membrane synthesis. Unlike azoles (which are fungistatic), terbinafine is fungicidal — it eradicates fungi rather than just inhibiting their growth.

Jublia vs Terbinafine: Cure Rates and Evidence

Trial results side by side:

  • Complete cure rate: Jublia (efinaconazole 10%): 15–18%; Terbinafine (oral): ~38%
  • Mycological cure rate: Jublia (efinaconazole 10%): ~54%; Terbinafine (oral): ~70% (FDA label)
  • Clinical success (clear/near-clear): Jublia (efinaconazole 10%): ~26–27%; Terbinafine (oral): Not reported on the same scale
  • Primary RCT: Jublia (efinaconazole 10%): Elewski et al. JAAD 2013 (two Phase 3 RCTs); Terbinafine (oral): FDA Lamisil label trials (placebo-controlled RCTs)
  • Evidence grade: Jublia (efinaconazole 10%): Moderate evidence; Terbinafine (oral): Strong evidence
  • Number of nails treated: Jublia (efinaconazole 10%): Topical to affected nails only; Terbinafine (oral): Systemic; treats all nails

Important context: “Complete cure” in nail fungus trials means negative mycology (culture + KOH) plus normal nail appearance. Even with the best-evidenced treatment (terbinafine), only about 38 in 100 patients achieve this. Cure rates in real-world practice may differ from controlled trial conditions. Our evidence grading methodology →

Jublia vs Terbinafine: Treatment Timeline

Jublia Timeline

Terbinafine Timeline

Jublia vs Terbinafine: Side Effects and Safety

Jublia Side Effects

Terbinafine Side Effects

When Jublia is preferred over terbinafine: Pre-existing liver disease, taking CYP2D6-sensitive medications, patient preference for avoiding systemic drugs, prior adverse reaction to oral antifungals.

Jublia vs Terbinafine: Cost

Jublia vs Terbinafine: Who Should Choose Which

Consider Jublia if:

Consider terbinafine if:

Important: This decision should be made with your prescribing physician. Both are prescription-only drugs. Confirm your diagnosis with a lab test (KOH smear or culture) before starting either treatment — about half of suspected nail fungus cases test negative.

Can You Use Jublia and Terbinafine Together?

Combination therapy (oral terbinafine + topical efinaconazole) has been studied in small trials. The rationale is that the oral agent delivers systemic antifungal action via the bloodstream, while the topical acts on the nail surface — potentially addressing the infection from both directions.

Some published small trials suggest improved mycological cure rates with combination therapy, but the evidence is limited and no large-scale RCT has established a standard combination protocol. Most guidelines do not currently recommend combination therapy as first-line.

Practical implication: Some prescribers use combination therapy for resistant cases or patients with very thick, severely involved nails. If you are not responding to monotherapy, discuss combination options with your dermatologist or podiatrist.

Options You Can Buy Without a Prescription

Prescription treatments need a doctor or podiatrist. If you want something you can buy today, these are the best options available without a prescription. None is FDA-approved to cure nail fungus, so expect slow, modest results and see a clinician if the nail gets worse.

Lamisil AT Cream (terbinafine 1%)

Over-the-counter terbinafine 1% cream. It is approved for athlete’s foot, ringworm and jock itch, not for nails, so use it on the skin around the nail and between the toes, where fungus often re-seeds the nail. Evidence for nails: Limited (skin-fungus approval data only). Typically about $10–$20.

Check Lamisil AT Cream price

Fungi-Nail Anti-Fungal Solution

Undecylenic acid 25% liquid with a brush applicator, for mild, early cases and the surrounding skin. Product evidence: Anecdotal (no trial of the product; undecylenic acid: Limited). Usually under $15.

Check Fungi-Nail Anti-Fungal Solution price

Kerasal Fungal Nail Renewal

Urea + lactic acid nail treatment that softens and visibly improves thick, discolored nails in 2–8 weeks. It is cosmetic, not an antifungal. Product evidence: Anecdotal (urea: Limited).

Check Kerasal Fungal Nail Renewal price

Jublia vs Terbinafine: Common Questions

By complete cure rate, no: oral terbinafine (~38%) outperforms Jublia (15–18%). Jublia is better in specific situations: when oral terbinafine is contraindicated (liver disease, drug interactions, patient preference). For the typical healthy adult with confirmed toenail fungus, oral terbinafine is the more effective and cost-effective choice. See full evidence comparison →

Oral terbinafine is the most effective treatment with the strongest evidence base (~38% complete cure in the FDA label trials; Lamisil prescribing information). The next-best evidence is for oral itraconazole. Prescription topicals (efinaconazole, ciclopirox) are second-line options. OTC products have limited-to-anecdotal evidence. No treatment cures nail fungus in 100% of patients. Full treatment guide →

Among prescription topicals, efinaconazole 10% (Jublia) has the strongest published RCT evidence (15–18% complete cure; Elewski, JAAD 2013). Ciclopirox 8% lacquer (Penlac) has also been FDA-approved for onychomycosis and has published trial data, with slightly lower mycological cure rates in head-to-head comparisons. Terbinafine vs ciclopirox comparison →

Terbinafine can cause liver enzyme elevation (hepatotoxicity) in a small proportion of patients. The rate of clinically significant hepatotoxicity is approximately 1 in 50,000–120,000 — rare, but potentially serious. Baseline liver function tests (LFTs) are recommended before starting. Terbinafine is contraindicated in patients with pre-existing liver disease. Report any unexplained fatigue, nausea, or jaundice to your prescribing physician immediately. Full terbinafine guide →

Onychomycosis is a fungal infection of the nail, most commonly caused by dermatophytes (Trichophyton rubrum in most cases). It affects up to about 1 in 10 adults (3–12%; AAFP 2015) and becomes more common with age. Lab confirmation (KOH smear or nail culture) is recommended before treating, as about half of suspected cases test negative (thickened or discolored nails can have non-fungal causes).

Sources

  1. L.I.ON. study. Terbinafine vs itraconazole for toenail onychomycosis. BMJ 1999;318:1031–1035.
  2. Elewski BE et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two Phase 3 multicenter, randomized, double-blind studies. JAAD 2013;68(4):600–608.
  3. FDA. Jublia (efinaconazole) prescribing information. fda.gov (accessed Nov 2026).
  4. FDA. Lamisil (terbinafine) prescribing information. fda.gov (accessed Nov 2026).
  5. Ferrari J. Fungal toenail infections (clinical review). Am Fam Physician 2015;92(2):132–133.
  6. AAD. Nail fungus: tips for managing. aad.org (accessed Nov 2026).
  7. Gupta AK, Mays RR. The impact of onychomycosis on quality of life. Skin Appendage Disord 2018;4(4):208–216.
  8. SingleCare. Jublia prices (4 mL). singlecare.com/prescription/jublia (prices updated Nov 16, 2026).
  9. Ortho Dermatologics. Rx Access Program terms for Jublia. orthorxaccess.com (accessed Nov 16, 2026).

Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Jublia and terbinafine are prescription drugs requiring physician evaluation. Always consult a qualified healthcare provider before starting, changing or stopping any medication.

Not sure which treatment fits your case?

Answer 4 quick questions and get a recommendation matched to your nails.